BMPR2 Readthrough Composition for Heritable PAH Nonsense Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for heritable pulmonary artery hypertension (hPAH) caused by nonsense mutations in the BMPR2 gene are ineffective, and existing readthrough compounds like G418 and PTC-124 show limited efficacy in restoring functional BMPR2 protein expression.
Innovation Solution
The use of GJ103, a novel SMRT compound, effectively reads through nonsense mutations in the BMPR2 gene, leading to increased expression and functional restoration of the BMPR2 protein, thereby addressing the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing readthrough compounds (G418, PTC-124) are used to treat hPAH caused by nonsense mutations in BMPR2 gene, then some protein expression may be restored, but the efficacy is limited and insufficient for effective treatment
Solution Approach 1:
The patent modifies chemical parameters of readthrough compounds by changing the core structure from traditional aminoglycosides or PTC-124 to a novel spiroindole-dihydropyrimidinone scaffold (Formula I), with specific substitutions at positions R1-R6 to optimize readthrough efficacy while maintaining safety profile
Solution Approach 2:
The invention creates a composite molecular structure combining spiroindole and dihydropyrimidinone moieties with various substituent groups (aryl, heteroaryl, alkyl, etc.) to achieve synergistic effects that enhance readthrough capability beyond what single traditional compounds can provide
2Quantity of substance
If higher doses of existing readthrough compounds are administered to improve protein expression, then more functional BMPR2 protein may be produced, but safety concerns and side effects increase
Solution Approach 1:
The novel compounds of Formula I achieve enhanced readthrough efficacy at lower doses by optimizing molecular parameters including substituent types (R1-R6), ring structures, and functional groups, allowing effective BMPR2 protein restoration without reaching toxic dose thresholds
Solution Approach 2:
The patent develops a new generation of readthrough compounds with improved pharmacokinetic properties that achieve therapeutic effect efficiently and are cleared from the body without accumulating to toxic levels, replacing older compounds that required higher sustained dosing
3Ease of manufacture
If traditional therapies are used for hPAH, then current treatment protocols can be maintained, but they are ineffective in addressing the underlying nonsense mutation pathology
Solution Approach 1:
The patent introduces small molecule readthrough compounds as intermediaries that bind to the ribosome-mRNA complex during translation, enabling the ribosome to read through the premature stop codon and continue synthesizing functional BMPR2 protein, thereby bridging the gap between the mutation and functional protein production
Solution Approach 2:
The invention provides compounds that can be administered before complete disease onset or progression, allowing prevention or early intervention in hPAH patients with BMPR2 nonsense mutations, potentially slowing or preventing disease development before irreversible damage occurs
Data Source
AI summary
The present disclosure relates generally to compositions and methods for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof. The method entails administering to the subject a compound of the present disclosure, such as GJ103 and a salt thereof.